Valneva VALN 深 沪
等待开盘 08-27 09:30:00 美东时间
6.695
-0.085
-1.25%
华盛通- 最 高6.80
- 今 开6.79
- 成交量 2.82万股
- 最 低 6.56
- 昨 收 6.78
- 总市值 6.35亿
- 52周最高 12.23
- 市盈率 静 --
- 换手率 0.03%
- 52周最低 4.75
- 委 比 -76.34%
- 总股本 9482.35万
- 历史最高 67.84
- 量 比 0.78
- 振 幅 3.54%
- 历史最低 3.62
- 每 手 1
- 风险率 2.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Applied Optoelectronics, SanDisk, Seagate And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq 100 futures falling over 100 points on Monday. Shares of Applied Optoelectronics Inc (NASDAQ:AAOI) fell sharply in pre-market trading after the company announced a $600 million at-the-market equity offering. Applied Optoelectronics shares d...
08-24 20:04
Notable trades: Netflix, Coca-Cola, Pfizer among notable names
Insider transactions were seen across major firms this week, including Netflix (NFLX), Merck (MRK), and Pfizer (PFE). The following trades took place between August 10 and August 14. Netflix (NFLX) Ch...
08-15 23:00
European Regulator Validates Pfizer and Valneva's Lyme Disease Vaccine Application
Valneva SE (NASDAQ:VALN) stock is surging on Friday after the company and its partner Pfizer Inc. (NYSE:PFE) announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, their Lyme disease vaccine candidate. The EMA will now commence...
08-15 00:46
Why Eton Pharmaceuticals Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Shares of Eton Pharmaceuticals Inc (NASDAQ:ETON) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results and issued FY26 revenue guidance above estimates. Eton Pharmaceuticals reported quarterly earnings of 43 cents per share which beat the...
08-14 16:37
欧洲药品管理局确认辉瑞与Valneva的莱姆病疫苗申请后，Valneva SE股价上涨12%，在SBF 120指数中领涨。
欧洲药品管理局确认辉瑞与Valneva的莱姆病疫苗申请后，Valneva SE股价上涨12%，在SBF 120指数中领涨。
08-14 15:05
Conference Call: Valneva Affirms FY2026 Sales Guidance of $169.795M-$187.360M vs $171.630M Est
Valneva (NASDAQ:VALN) affirms FY2026 sales outlook from $169.795 million-$187.360 million to $169.795 million-$187.360 million vs $171.630 million estimate.
08-13 22:20
Valneva GAAP EPS of -€0.35, revenue of €65.84M; reaffirms FY 2026
Valneva press release (VALN): 1H GAAP EPS of -€0.35. Revenue of €65.84M (-32.5% Y/Y). Solid cash position of €121.5 million as of end June 2026. Financial Outlook Despite the continued adverse impact ...
08-13 14:05
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
Tonix Pharmaceuticals announced alignment with the FDA on the design of its adaptive Phase 2 study for TNX-4800, a long-acting monoclonal antibody targeting Lyme disease prevention. TNX-4800, which targets the OspA protein on Borrelia bacteria, offers a rapidly acting alternative to vaccines with potential advantages in efficacy and tolerability. The Phase 2 study, planned to begin in early 2027, will involve approximately 3,300 participants over...
08-03 11:00
